In advance of today’s #OCDchat with Dr. Wayne Goodman, who will be answering your questions about OCD medication, we wanted to give a special preview to Dr. Goodman’s article in the newest issue of the OCD Newsletter. The OCD Newsletter is a quarterly publication featuring research news, articles from the Therapy Community, and featuring essays and creative writing from individuals with OCD. The Newsletter is usually available only to members of the IOCDF (learn more about membership here), but we wanted to make this article available to everyone in advance of today’s chat.
Towards New Medications for Refractory OCD
Current psychotherapy and medication treatments for OCD can be of help to many who suffer from the disorder. Unfortunately, as many as a quarter of patients do not experience much benefit from these standard treatments, such as selective serotonin reuptake inhibitors (SSRIs) or Exposure and Response Prevention (ERP), even when they are used well. The development of new treatment options for these individuals is an urgent clinical and research need. This article looks at up-and-coming research on medications that affect the brain’s glutamate system as a strategy for treating refractory OCD (also known as “treatment-resistant” OCD). Download PDF of entire article here.
Read the article, and then bring your questions about OCD medications to today’s #OCDchat at 12noon Eastern. Dr. Goodman will be our guest panelist, and will be joined by moderators Jeff Szymanski, PhD, clinical psychologist and executive director of the IOCDF, and Carly Bourne, director of communications for the IOCDF.
To join the chat, just go to iocdf.org/chat. No Twitter or Facebook accounts needed to participate. See you today at 12pm ET!